Back to Directory Richard M. Rutstein Email rutstein@email.chop.edu Institution Children's Hospital of Philadelphia Title Medical Director, Special Immunlogy Service Request an Update Affiliated Studies P1020A: A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents DAIDS Number 10037 Research Area Treatment Study Status Concluded P1053: Evaluation PI-Containing vs. Non-PI-Containing Salvage Regimens. DAIDS Number 10131 Research Area Other Study Status Concluded P1090: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine DAIDS Number 10850 Research Area Treatment Study Status Concluded
P1020A: A Phase I/II, Open-Label, Pharmacokinetic and Safety Study of a Novel Protease Inhibitor (BMS-232632, Atazanavir, ATV, Reyataz) in Combination Regimens in Antiretroviral Therapy (ART)-Naive and Experienced HIV-infected Infants, Children and Adolescents DAIDS Number 10037 Research Area Treatment Study Status Concluded
P1053: Evaluation PI-Containing vs. Non-PI-Containing Salvage Regimens. DAIDS Number 10131 Research Area Other Study Status Concluded
P1090: Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine DAIDS Number 10850 Research Area Treatment Study Status Concluded
